Your fact-checks will appear here
Japanese monk
No dementia drug developed or publicly tied to Elon Musk has received FDA or EMA approval as of December 2025 in the available reporting. Neuralink — the Musk-associated company most often linked to n...
A broad pipeline of tau-based approaches—small molecules that block aggregation or modify tau chemistry, immunotherapies that target extracellular tau, gene‑ and RNA‑based tactics that lower tau produ...
Patients prescribed 2025 FDA‑approved Alzheimer’s drugs face variable but often substantial out‑of‑pocket exposure that depends on the drug’s list price, Medicare cost‑sharing rules, required diagnost...
Clinical trials reported to show cognitive benefits in recent coverage include CT1812 (zervimesine) in dementia with Lewy bodies — the SHIMMER program reported safety and “cognitive improvements” — an...
Eisai and Biogen’s lecanemab (Leqembi) program used large Phase 3 trials and extensive post‑marketing safety reviews, including an 18‑month initiation then maintenance dosing schema and multiple regul...
Neurocept is presented in consumer press as an over‑the‑counter brain‑health supplement with no published, product‑level clinical trials in the provided sources, while aducanumab and lecanemab are pre...
For mild cognitive impairment (MCI) there is no single approved “cure” medication; clinicians focus on diagnosis, monitoring, treating reversible causes and enrolling patients in trials (StatPearls; N...
Meals on Wheels programs rely heavily on as their principal non-governmental funding streams, while federal funding—primarily through the Older Americans Act—covers a substantial but not dominant shar...